Jeremy Grantham Gilead Sciences, Inc. Transaction History

Grantham, Mayo, Van Otterloo & Co. LLC

$31.4 Billion
Q3 2024

A detailed history of Jeremy Grantham (Grantham, Mayo, Van Otterloo & Co. LLC) transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Grantham, Mayo, Van Otterloo & Co. LLC holds 60,638 shares of GILD stock, worth $5.37 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

60,638

Previous 233,261 74.0%

Holding current value

$5.37 Million

Previous $16 Million 68.25%

% of portfolio

0.02%

Previous 0.05%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$66.59 - $83.99 $11.5 Million - $14.5 Million	-172,623 Reduced 74.0%	60,638 $5.08 Million
Q2 2024 Aug 13, 2024	BUY	$63.15 - $72.88 $14.7 Million - $17 Million	233,261 New	233,261 $16 Million
Q4 2023 Feb 13, 2024	BUY	$73.27 - $83.09 $2.71 Million - $3.08 Million	37,031 Added 14.86%	286,270 $23.2 Million
Q3 2023 Nov 13, 2023	SELL	$73.94 - $80.67 $1.52 Million - $1.66 Million	-20,565 Reduced 7.62%	249,239 $18.7 Million
Q2 2023 Aug 14, 2023	SELL	$76.01 - $86.7 $1.51 Million - $1.72 Million	-19,880 Reduced 6.86%	269,804 $20.8 Million
Q1 2023 May 12, 2023	BUY	$77.31 - $88.08 $3.46 Million - $3.94 Million	44,704 Added 18.25%	289,684 $24 Million
Q4 2022 Feb 13, 2023	SELL	$62.32 - $89.47 $18.6 Million - $26.8 Million	-299,016 Reduced 54.97%	244,980 $21 Million
Q3 2022 Nov 10, 2022	SELL	$59.54 - $68.01 $2.14 Million - $2.44 Million	-35,900 Reduced 6.19%	543,996 $33.6 Million
Q2 2022 Aug 12, 2022	BUY	$57.72 - $65.01 $5.26 Million - $5.93 Million	91,200 Added 18.66%	579,896 $35.8 Million
Q1 2022 May 13, 2022	BUY	$57.92 - $72.58 $4.33 Million - $5.42 Million	74,696 Added 18.04%	488,696 $29.1 Million
Q4 2021 Feb 11, 2022	SELL	$64.88 - $73.64 $123,271 - $139,916	-1,900 Reduced 0.46%	414,000 $30.1 Million
Q3 2021 Nov 12, 2021	BUY	$67.69 - $73.03 $2.94 Million - $3.17 Million	43,400 Added 11.65%	415,900 $29.1 Million
Q2 2021 Aug 12, 2021	BUY	$63.47 - $69.35 $5.62 Million - $6.14 Million	88,600 Added 31.21%	372,500 $25.7 Million
Q1 2021 May 13, 2021	BUY	$60.0 - $68.46 $6.53 Million - $7.45 Million	108,870 Added 62.2%	283,900 $18.3 Million
Q4 2020 Feb 12, 2021	BUY	$56.65 - $64.55 $5.31 Million - $6.05 Million	93,700 Added 115.21%	175,030 $10.2 Million
Q3 2020 Nov 13, 2020	BUY	$62.1 - $78.08 $6,210 - $7,808	100 Added 0.12%	81,330 $5.14 Million
Q2 2020 Aug 13, 2020	BUY	$72.34 - $84.0 $2.28 Million - $2.64 Million	31,461 Added 63.21%	81,230 $6.25 Million
Q1 2020 May 14, 2020	SELL	$62.63 - $80.22 $7.68 Million - $9.84 Million	-122,655 Reduced 71.14%	49,769 $3.72 Million
Q4 2019 Feb 13, 2020	SELL	$61.62 - $67.78 $2.59 Million - $2.85 Million	-42,076 Reduced 19.62%	172,424 $11.2 Million
Q3 2019 Nov 13, 2019	SELL	$62.51 - $69.0 $2.39 Million - $2.64 Million	-38,300 Reduced 15.15%	214,500 $13.6 Million
Q2 2019 Aug 13, 2019	BUY	$61.87 - $69.38 $426,903 - $478,721	6,900 Added 2.81%	252,800 $17.1 Million
Q1 2019 May 14, 2019	BUY	$62.53 - $70.05 $15.4 Million - $17.2 Million	245,900 New	245,900 $16 Million
Q3 2018 Nov 14, 2018	SELL	$71.28 - $78.92 $684,288 - $757,632	-9,600 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$64.88 - $75.68 $19,464 - $22,704	300 Added 3.23%	9,600 $680,000
Q4 2017 Feb 14, 2018	BUY	$71.15 - $83.52 $661,695 - $776,736	9,300 New	9,300 $666,000
Q3 2017 Nov 14, 2017	SELL	$72.11 - $85.47 $490,348 - $581,196	-6,800 Closed	0 $0
Q2 2017 Aug 14, 2017	BUY	N/A	6,800	6,800 $481,000

Others Institutions Holding GILD

# of Institutions

1,923

Shares Held

994M

Call Options Held

10.5M

Put Options Held

9.75M

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $111B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track Jeremy Grantham's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Grantham, Mayo, Van Otterloo & Co. LLC, based on Form 13F filings with the SEC.

News

Stay updated on Grantham, Mayo, Van Otterloo & Co. LLC and Jeremy Grantham with notifications on news.

Account